Advertisement

O06Self-managed abortion outcomes for pregnancies of 9–22 weeks’ gestation: Results from a prospective, observational study in three countries

      This paper is only available as a PDF. To read, Please Download here.

      Objectives

      The literature on self-managed abortion at later gestations is sparse, and more information is urgently needed in the US and elsewhere where this practice may become increasingly common. This analysis offers novel results on the effectiveness of self-managed medication abortion among people with pregnancies >9 weeks.

      Methods

      In 2019–2020, as a part of The Studying Accompaniment Model Feasibility and Effectiveness (SAFE) Study, we recruited callers to safe-abortion hotlines in Argentina, Nigeria, and Southeast Asia who were seeking support for self-managed medication abortion. Via phone, participants completed a baseline survey prior to taking the medications, and up to three follow-up surveys over four weeks to ascertain abortion outcomes.

      Results

      We recruited 1,351 participants, of which 264 self-managed an abortion for a pregnancy that was 9–22 weeks’ gestation; 149 (56%) respondents used mifepristone and misoprostol, while 115 (44%) used misoprostol alone. One week after taking the pills, 222 (91%) participants had a complete abortion — 87% with pills alone, and 4% with additional intervention. At last follow-up, 95% of participants had had a complete abortion (89% with pills alone, 5% with additional intervention; 93% of combined regimen users, and 97% of misoprostol-alone users). A minority of participants sought healthcare at a clinic or hospital at any point (30% of combined regimen users, 15% of misoprostol-alone users). Among those seeking care, most (60%) did so to confirm abortion completion, and a small minority (1.5%) received treatment indicative of a serious complication (blood transfusion).

      Conclusions

      Self-managed medication abortion can be a safe and effective option for ending a pregnancy at 9+ weeks’ gestation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect